Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2006

View Archived Issues

AEterna Zentaris presents pipeline round-up

Orphan drug designation for Valortim in treatment of anthrax infection

Phase III efficacy trials begin for Technosphere Insulin

Priority review for TMC-114

Infinity and Novartis collaborate on Bcl-2 family inhibitors

Nereus closes second tranche of financing

Velcade studied in combination with pemetrexed for advanced NSCLC

Enrollment completed in phase I study of Chemophase for bladder cancer

Endovasc submits phase IIIa Liprostin protocol to FDA

Positive results for CX-717 in adults with ADHD

Positive Advisory Committee vote for Cubicin sNDA

Anti-rabies monoclonal antibody combination effective in vitro and in vivo

Mometasone nasal spray reduces nasal polyps

Intraperitoneal chemotherapy beneficial in patients with ovarian cancer

Safety, pharmacokinetics and comparative efficacy of BAY-59-7939 evaluated

LS-104 targets mutated Flt3 to provide enhanced anti-AML activity

Novel agents for nephritis disclosed in recent Shionogi patent

Xyrem launched for excessive daytime sleepiness in narcolepsy patients

Dasatinib NDA accepted for priority review

Recent patents cover therapeutic agents for neurological disorders

Novel antidiabetic agents disclosed in recent patents

S-236 cream may be used to promote barrier repair in atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...